Panacea Biotec rises on launching anti-diabetic drug ‘TENEPAN’

29 Jun 2016 Evaluate

Panacea Biotec is currently trading at Rs. 131.65, up by 4.40 points or 3.46% from its previous closing of Rs. 127.25 on the BSE.

The scrip opened at Rs. 131.50 and has touched a high and low of Rs. 132.00 and Rs. 128.00 respectively. So far 13,000 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 178.10 on 10-Aug-2015 and a 52 week low of Rs. 83.90 on 12-Feb-2016.

Last one week high and low of the scrip stood at Rs. 132.00 and Rs. 110.45 respectively. The current market cap of the company is Rs. 806.37 crore.

The promoters holding in the company stood at 74.65%, while Institutions and Non-Institutions held 0.69% and 24.66% respectively.

Panacea Biotec, the country’s third largest biotechnology company has introduced indigenously developed high quality anti-diabetic drug, TENEPAN (Teneligliptin), for treatment of Type 2 Diabetes Mellitus (T2DM). TENEPAN (Teneligliptin) aims to improve accessibility of this treatment for the benefit of patients at an affordable cost as part of company’s commitment to Government of India’s ‘Make in India’ mission.

Panacea Biotec is the third largest biotechnology company as well as among the top 50 pharmaceutical companies of India. The company has product portfolio that’s caters therapeutics areas like pain management, diabetes and cardiovascular management, renal disease management, osteoporosis management, anti-tubercular, gastro-intestinal.



Panacea Biotec Share Price

397.45 -9.60 (-2.36%)
29-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1717.50
Dr. Reddys Lab 1268.60
Cipla 1494.40
Zydus Lifesciences 904.00
Lupin 2079.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×